Versiti Acquires Cenetron Central Laboratories and Salus IRB

Published on: 

Applied Clinical Trials

 Versiti, has announced the acquisition of Texas-based Cenetron Central Laboratories, and its subsidiary, Salus IRB, offering both organizations the opportunity to expand clinical trial services and expertise.

“By joining forces with an industry leader such as Cenetron, we gain the strength of an organization that specializes in pre-analytical activities that are critical to the success of clinical trials,” said Versiti President and CEO Chris Miskel. “Clinical trials are critical to medical advances that translate to patient care.”   

Cenetron will provide Versiti’s diagnostic laboratories with a spectrum of clinical trial solutions from project initiation, kit development and sample logistics, specialized testing, data management, and project management. 

The acquisition will not impact Cenetron’s 40 employees, and the laboratory will maintain its name and current location in Austin. Versiti, headquartered in Milwaukee, has 2,000 employees at its locations in Illinois, Indiana, Michigan, Ohio and Wisconsin.


“Versiti and Cenetron are dedicated to a common mission of advancing medical science, and patient care, through clinical trials,” said Cenetron President Dwight DuBois, M.D. “The entire Cenetron organization is both excited and proud to be aligned with an organization with Versiti's sterling reputation." 

Dr. DuBois will remain at Cenetron as the laboratory’s medical director.